UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Synthetic lethality between ATR and POLA1 reveals a potential new target for individualized cancer therapy

Neoplasia (New York, N.Y.), 2024-11, Vol.57, p.101038, Article 101038

2024

Volltextzugriff (PDF)

Batf-dependent Th17 cells critically regulate IL-23 driven colitis-associated colon cancer

Gut, 2016-07, Vol.65 (7), p.1139-1150

2016

Volltextzugriff (PDF)

Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group

BMC cancer, 2018-12, Vol.18 (1), p.1298-10, Article 1298

2018

Volltextzugriff (PDF)

The POLD1R689W variant increases the sensitivity of colorectal cancer cells to ATR and CHK1 inhibitors

Scientific reports, 2020-11, Vol.10 (1), Article 18924

2020

Volltextzugriff (PDF)

Inactivation of PRIM1 Function Sensitizes Cancer Cells to ATR and CHK1 Inhibitors

Neoplasia (New York, N.Y.), 2018-11, Vol.20 (11), p.1135-1143

2018

Volltextzugriff (PDF)

Absence of E-Cadherin Expression Distinguishes Noncohesive from Cohesive Pancreatic Cancer

Clinical cancer research, 2008-01, Vol.14 (2), p.412-418

2008

Volltextzugriff (PDF)

Inhibition of Ataxia Telangiectasia‐ and Rad3 ‐Related Function Abrogates the In Vitro and In Vivo Tumorigenicity of Human Colon Cancer Cells Through Depletion of the CD133+ Tumor‐Initiating Cell Fraction

Stem cells (Dayton, Ohio), 2011-03, Vol.29 (3), p.418-429

2011

Volltextzugriff (PDF)

Targeting Fanconi Anemia/BRCA2 Pathway Defects in Cancer: The Significance of Preclinical Pharmacogenomic Models

Clinical cancer research, 2007-01, Vol.13 (1), p.4-10

2007

Volltextzugriff (PDF)

Loss of TRAIL-receptors is a recurrent feature in pancreatic cancer and determines the prognosis of patients with no nodal metastasis after surgery

PloS one, 2013-02, Vol.8 (2), p.e56760-e56760

2013

Volltextzugriff (PDF)

Tivantinib (ARQ 197) affects the apoptotic and proliferative machinery downstream of c-MET: role of Mcl-1, Bcl-xl and Cyclin B1

Oncotarget, 2015-09, Vol.6 (26), p.22167-22178

2015

Volltextzugriff (PDF)

Knock-in of mutant K-ras in nontumorigenic human epithelial cells as a new model for studying K-ras-mediated transformation

Cancer research (Chicago, Ill.), 2007-09, Vol.67 (18), p.8460-8467

2007

Volltextzugriff (PDF)

In vivo Therapeutic Responses Contingent on Fanconi Anemia/BRCA2 Status of the Tumor

Clinical cancer research, 2005-10, Vol.11 (20), p.7508-7515

2005

Volltextzugriff (PDF)

Identifying allelic loss and homozygous deletions in pancreatic cancer without matched normals using high-density single-nucleotide polymorphism arrays

Cancer research (Chicago, Ill.), 2006-08, Vol.66 (16), p.7920-7928

2006

Volltextzugriff (PDF)

Microsatellite instability, KRAS mutations and cellular distribution of TRAIL-receptors in early stage colorectal cancer

PloS one, 2012-12, Vol.7 (12), p.e51654-e51654

2012

Volltextzugriff (PDF)

High cancer-specific expression of mesothelin (MSLN) is attributable to an upstream enhancer containing a transcription enhancer factor-dependent MCAT motif

Cancer research (Chicago, Ill.), 2007-10, Vol.67 (19), p.9055-9065

2007

Volltextzugriff (PDF)

Absence of specific cell killing of the BRCA2-deficient human cancer cell line CAPAN1 by poly(ADP-ribose) polymerase inhibition

Cancer biology & therapy, 2005-07, Vol.4 (7), p.703-706

2005

Volltextzugriff (PDF)

Genetic inactivation of the Fanconi anemia gene FANCC identified in the hepatocellular carcinoma cell line HuH-7 confers sensitivity towards DNA-interstrand crosslinking agents

Molecular cancer, 2010-05, Vol.9 (1), p.127-127, Article 127

2010

Volltextzugriff (PDF)

Targeted Disruption of FANCC and FANCG in Human Cancer Provides a Preclinical Model for Specific Therapeutic Options

Gastroenterology (New York, N.Y. 1943), 2006-06, Vol.130 (7), p.2145-2154

2006

Volltextzugriff (PDF)

Supraclavicular Approach for Central Venous Catheterization: “Safer, Simpler, Speedier”

Journal of the American College of Surgeons, 2007-09, Vol.205 (3), p.514-516

2007

Volltextzugriff (PDF)

Ultra-fast high-resolution agarose electrophoresis of DNA and RNA using low-molarity conductive media

BioTechniques, 2004-10, Vol.37 (4), p.598-602

2004

Volltextzugriff (PDF)

Distinguishing Rational from Irrational Applications of Pharmacogenetic Synergies from the Bench to Clinical Trials

Cell cycle (Georgetown, Tex.), 2007-06, Vol.6 (11), p.1336-1341

2007

Volltextzugriff (PDF)

Incidence, outcome and risk stratification tools for venous thromboembolism in advanced pancreatic cancer – A retrospective cohort study

Thrombosis research, 2017-09, Vol.157, p.9-15

2017

Volltextzugriff (PDF)

Perioperative or adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: Quality of life results of the randomized phase II AIO-NEONAX trial

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.694-694

2023

Volltextzugriff (PDF)

Gene-specific selection against experimental fanconi anemia gene inactivation in human cancer

Cancer biology & therapy, 2007-05, Vol.6 (5), p.654-660

2007

Volltextzugriff (PDF)

1 – 25 von 71

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(60)
Mit Volltextzugriff
(68)

Publikationsform

Artikel
(66)
Berichte
(5)

Sprache

Englisch
(70)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Synthetic lethality between ATR and POLA1 reveals a potential new target for individualized cancer therapy

Batf-dependent Th17 cells critically regulate IL-23 driven colitis-associated colon cancer

Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group

The POLD1R689W variant increases the sensitivity of colorectal cancer cells to ATR and CHK1 inhibitors

Inactivation of PRIM1 Function Sensitizes Cancer Cells to ATR and CHK1 Inhibitors

Absence of E-Cadherin Expression Distinguishes Noncohesive from Cohesive Pancreatic Cancer

Inhibition of Ataxia Telangiectasia‐ and Rad3 ‐Related Function Abrogates the In Vitro and In Vivo Tumorigenicity of Human Colon Cancer Cells Through Depletion of the CD133+ Tumor‐Initiating Cell Fraction

Targeting Fanconi Anemia/BRCA2 Pathway Defects in Cancer: The Significance of Preclinical Pharmacogenomic Models

Loss of TRAIL-receptors is a recurrent feature in pancreatic cancer and determines the prognosis of patients with no nodal metastasis after surgery

Tivantinib (ARQ 197) affects the apoptotic and proliferative machinery downstream of c-MET: role of Mcl-1, Bcl-xl and Cyclin B1

Knock-in of mutant K-ras in nontumorigenic human epithelial cells as a new model for studying K-ras-mediated transformation

In vivo Therapeutic Responses Contingent on Fanconi Anemia/BRCA2 Status of the Tumor

Identifying allelic loss and homozygous deletions in pancreatic cancer without matched normals using high-density single-nucleotide polymorphism arrays

Microsatellite instability, KRAS mutations and cellular distribution of TRAIL-receptors in early stage colorectal cancer

High cancer-specific expression of mesothelin (MSLN) is attributable to an upstream enhancer containing a transcription enhancer factor-dependent MCAT motif

Absence of specific cell killing of the BRCA2-deficient human cancer cell line CAPAN1 by poly(ADP-ribose) polymerase inhibition

Genetic inactivation of the Fanconi anemia gene FANCC identified in the hepatocellular carcinoma cell line HuH-7 confers sensitivity towards DNA-interstrand crosslinking agents

Targeted Disruption of FANCC and FANCG in Human Cancer Provides a Preclinical Model for Specific Therapeutic Options

Supraclavicular Approach for Central Venous Catheterization: “Safer, Simpler, Speedier”

Ultra-fast high-resolution agarose electrophoresis of DNA and RNA using low-molarity conductive media

Distinguishing Rational from Irrational Applications of Pharmacogenetic Synergies from the Bench to Clinical Trials

Incidence, outcome and risk stratification tools for venous thromboembolism in advanced pancreatic cancer – A retrospective cohort study

Perioperative or adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: Quality of life results of the randomized phase II AIO-NEONAX trial

Gene-specific selection against experimental fanconi anemia gene inactivation in human cancer

Nanoliposomal Irinotecan With Fluorouracil and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Cholangiocarcinoma: A Phase II Study of the AIO Hepatobiliary-YMO Cancer Groups (NIFE-AIO-YMO HEP-0315)

Suchergebnisse filtern